Sirona Biochem Corp. (SBM.V)
- GlobeNewswire
Sirona Biochem Announces Debenture Financing
VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “Convertible Debentures”). The Company is offering Convertible Debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $1,500,000 (the “Offering”). Each Debenture Unit will have a
- Simply Wall St.
Sirona Biochem Full Year 2022 Earnings: CA$0.015 loss per share (vs CA$0.01 loss in FY 2021)
Sirona Biochem ( CVE:SBM ) Full Year 2022 Results Key Financial Results Revenue: CA$671.9k (up 151% from FY 2021). Net...
- GlobeNewswire
Sirona Biochem Receives Antiviral Testing Results
VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce it has received results from its research collaboration with the International Centre for Genetic Engineering and Biotechnology (“ICGEB”) to advance Sirona’s antiviral library of compounds. The ICGEB has successfully screened a library of 20 compounds produced at Sirona’s subsidiary TFChem as potential inhibitors of SARS-CoV-2 using specialize
